Torrent Pharmaceuticals Ltd — Stock Report

Torrent Pharmaceuticals Ltd (often abbreviated as Torrent Pharma) is a major Indian pharmaceutical company with a strong presence in domestic branded formulations and a growing international footprint. The business operates across multiple therapeutic segments including cardiovascular, gastrointestinal, central nervous system, and more specialty-oriented areas, and is actively expanding its global reach. In its Q1 FY26 results, Torrent Pharma reported consolidated revenue of approximately ₹3,178 crore—an ~11% increase year-on-year. Net profit rose around 20% to about ₹548 crore. Its domestic India business grew ~11% to ~₹1,811 crore, and the US business rose ~19% to ~₹308 crore, while operating EBITDA stood at ~₹1,032 crore with a margin of ~32.5%. In the full year FY25, the company delivered revenue of ~₹11,516 crore (up ~7% YoY) with net profit of ~₹1,911 crore (up ~15% YoY). Torrent’s strengths lie in its durable domestic branded business—which often outpaces the Indian pharmaceutical market growth—its improving international launches (especially in the US), and a focus on higher-margin therapies. The company is also making a bold move on the inorganic front: it has announced a major acquisition deal for JB Chemicals & Pharmaceuticals Ltd (to become a stronger challenger in the Indian pharma market) which could materially enhance scale and portfolio breadth. However, there are notable risks. Growth is still moderate for the size of the business, especially in international markets which face currency headwinds (for example the Brazilian real depreciation), regulatory challenges (US FDA inspections/pending ANDA approvals), and execution risk from large acquisitions (including the funding and integration of JB Chemicals). Valuation is elevated reflecting expectations of robust growth ahead and strategic expansion. Investors are being asked to believe that Torrent will convert its opportunities into sustained earnings increases.